Incidence and risk factors of retinopathy in Egyptian patients with chronic hepatitis C virus treated with pegylated interferon plus ribavirin

International Journal of Infectious Diseases

Volumn 16, Issue 1, 2012, Pages

  Fouad, Yasser M ^a   Khalaf, Hanaa ^a   Ibraheem, Hala ^a   Rady, Heba ^a   Helmy, Amal K ^a  

^a MINIA UNIVERSITY   (Egypt)

Author keywords

Chronic hepatitis C; Peginterferon ribavirin therapy; Retinopathy

Indexed keywords

HEMOGLOBIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; RIBAVIRIN; RNA;

ADULT; ARTICLE; COLOR VISION; CONTROLLED STUDY; DIABETES MELLITUS; EGYPT; FEMALE; FIBROSIS; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTENSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PROSPECTIVE STUDY; RETINA HEMORRHAGE; RETINOPATHY; RISK FACTOR; THROMBOCYTE COUNT; VISUAL ACUITY; VISUAL DISORDER; VISUAL FIELD;

ADULT; ANTIVIRAL AGENTS; EGYPT; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RETINAL DISEASES; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS; YOUNG ADULT;

EID: 84855328539     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2011.09.022     Document Type: Article

References (28)

1. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
2. Hadziyannis S.J., Sette H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355.
3. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
4. Quesada J.R., Talpaz M., Rios A., Kurzrock R., Gutterman J.U. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986, 4:234-243.
5. Zegans M.E., Anninger W., Chapman C., Gordon S.R. Ocular manifestations of hepatitis C virus infection. Curr Opin Ophthalmol 2002, 13:423-427.
6. Fodor M., Nagy V., Berta A., Tornai I., Pfliegler G. Hepatitis C virus presumably associated bilateral consecutive anterior ischemic optic neuropathy. Eur J Ophthalmol 2008, 18:313-315.
7. Misiuk-Hojło M., Michałowska M., Banach I. Ocular manifestations during hepatitis C infection. Przegl Epidemiol 2007, 61:545-550.
8. Hayasaka S., Fujii M., Yamamoto Y., Noda S., Kurome H., Sasaki M. Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa. Br J Ophthalmol 1995, 79:150-152.
9. Sugano S., Suzuki T., Watanabe M., Ohe K., Ishii K., Okajima T. Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C. Am J Gastroenterol 1998, 93:2441-2444.
10. Kawano T., Shigehira M., Uto H., Nakama T., Kato J., Hayashi K., et al. Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol 1996, 91:309-313.
11. Saito H., Ebinuma H., Nagata H., Inagaki Y., Saito Y., Wakabayashi K., et al. Interferon-associated retinopathy in a uniform regimen of natural interferon-alpha therapy for chronic hepatitis C. Liver 2001, 21:192-197.
12. Cuthbertson F.M., Davies M., McKibbin M. Is screening for interferon retinopathy in hepatitis C justified?. Br J Ophthalmol 2004, 88:1518-1520.
13. Jain K., Lam W.C., Waheeb S., Thai Q., Heathcote J. Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br J Ophthalmol 2001, 85:1171-1173.
14. Bajaire B.J., Paipilla D.F., Arrieta C.E., Oudovitchenko E. Mixed vascular occlusion in a patient with interferon-associated retinopathy. Case Report Ophthalmol 2011, 2:23-29.
15. Burgueño-Montañés C., Pérez-álvarez R. Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis C. Arch Soc Esp Oftalmol 2011, 86:193-195.
16. Stoffelns B.M. Interferon causes ischemic ocular diseases-case studies and review of the literature. Klin Monbl Augenheilkd 2006, 223:367-371.
17. Avila M.P., Freitas A.M., Isaac D.L., Bastos A.L., Pena R.V. [Retinopathy in a patient with hepatitis C treated with pegylated interferon and ribavirin: case report]. Arq Bras Oftalmol 2006, 69:255-259.
18. Mantel I., Konstantinidis L., Zografos L. Interferon-associated retinopathy-a case report. Klin Monbl Augenheilkd 2007, 224:350-352.
19. Guyer D.R., Tiedeman J., Yannuzzi L.A., Slakter J.S., Parke D., Kelley J., et al. Interferon associated retinopathy. Arch Ophthalmol 1993, 111:350-356.
20. Sidky Y., Borden E. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987, 47:5155-5161.
21. Miller J.W., Stinson W.G., Folkman J. Regression of experimental iris neovascularization with systemic alpha-interferon. Ophthalmology 1993, 100:9-14.
22. Chisholm J.A., Williams G., Spence E., Parks S., Keating D., Gavin M., et al. Retinal toxicity during pegylated alpha-interferon therapy for chronic hepatitis C: a multifocal electroretinogram investigation. Aliment Pharmacol Ther 2005, 21:723-732.
23. Malik N.N., Sheth H.G., Ackerman N., Davies N., Mitchell S.M. A prospective study of change in visual function in patients treated with pegylated interferon alpha for hepatitis C in the UK. Br J Ophthalmol 2008, 92:256-258.
24. Panetta J.D., Gilani N. Interferon-induced retinopathy and its risk in patients with diabetes and hypertension undergoing treatment for chronic hepatitis C virus infection. Aliment Pharmacol Ther 2009, 30:597-602.
25. Kim E.T., Kim L.H., Lee J.I., Chin H.S. Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin. Jpn J Ophthalmol 2009, 53:598-602.
26. Nakamura T., Takahashi H., Koike N., Mitsutaka M., Soda M., Kimu M. Retinopathy during interferon treatment in combination with ribavirin for chronic hepatitis C. Nippon Ganka Gakkai Zasshi 2005, 109:748-752.
27. Sharrett A.R., Hubbard L.D., Cooper L.S., Sorlie P.D., Brothers R.J., Nieto F.J., et al. Retinal arteriolar diameters and elevated blood pressure: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 1999, 150:263-270.
28. Okuse C., Yotsuyanagi H., Nagase Y., Kobayashi Y., Yasuda K., Koike K., et al. Risk factors for retinopathy associated with interferon α-2b and ribavirin combination therapy in patients with chronic hepatitis C. World J Gastroenterol 2006, 12:3756-3759.